Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-BRAIN
jRCTs051220059Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Intracranial overall response rate. Started Nov 2022; status: active, not recruiting.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051220059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220059.